The Journal of Immunology, Vol 132, Issue 3 1197-1201, Copyright © 1984 by American Association of Immunologists

ARTICLES

Immunoglobulin production by human peripheral lymphocytes induced by anti-C3 receptor antibodies

MR Daha, AC Bloem and RE Ballieux

The exact function of receptors for C3b (CR1), which are present on B lymphocytes, is not clear. The present studies were performed to determine the influence of heterologous anti-CR1 on the production of IgM, IgG, and IgA by human peripheral B lymphocytes in vitro. Anti-CR1, raised in rabbits by immunization with purified erythrocyte CR1, was rendered immunospecific and was converted to F(ab')2 and Fab' by enzyme digestion. Pre-immune F(ab')2 and Fab' served as controls. Normal human blood T lymphocytes and T cell-depleted mononuclear cells were cultured for 6 days in RPMI medium and 10% heated fetal calf serum with a low dose (7 micrograms/ml) of pokeweed mitogen (PWM) alone or with PWM and F(ab')2-anti-CR1. In control experiments the effects of F(ab')2-anti- CR1 without PWM and of pre-immune F(ab')2, Fab'-anti-CR1 and pre-immune Fab' in combination with PWM were also tested. When PWM and F(ab')2- anti-CR1 were present simultaneously, 4.3 X 10(3), 2.5 X 10(3), and 1.8 X 10(3) ng/ml of IgM, IgG, and IgA were synthesized, respectively, in cultures containing 4.5 X 10(5) mononuclear blood cells. All other combinations resulted in synthesis of less than 250 ng/ml of each class of Ig. The presence of purified CR1 in the cultures containing PWM and F(ab')2-anti-CR1 caused a dose-dependent decrease of Ig synthesis. By culturing B cells isolated by E-C3b rosetting with T cells and monocytes, the anti-CR1 responding population was demonstrated to be mainly in the CR1-rich B cell fraction. Fab'-anti-CR1 at high doses was also able to stimulate Ig production in the presence of low concentrations of PWM. These data suggest that triggering of CR1 on B cells results in modulation of antibody production and that triggering of CR1 with more than one antibody is required for an optimal response.

This article has been cited by other articles:

				P. GERGELY JR, A. ISAAK, Z. SZEKERES, J. PRECHL, A. ERDEI, Z. B. NAGY, J. GERGELY, and G. POOR Altered Expression of Fc{gamma} and Complement Receptors on B Cells in Systemic Lupus Erythematosus Ann. N.Y. Acad. Sci., June 1, 2007; 1108(1): 183 - 192. [Abstract] [Full Text] [PDF]

				R. T.K. Pang, T. C.W. Poon, K.C. A. Chan, N. L.S. Lee, R. W.K. Chiu, Y.-K. Tong, R. M.Y. Wong, S. S.C. Chim, S. M. Ngai, J. J.Y. Sung, et al. Serum Proteomic Fingerprints of Adult Patients with Severe Acute Respiratory Syndrome Clin. Chem., March 1, 2006; 52(3): 421 - 429. [Abstract] [Full Text] [PDF]

				M. Jozsi, J. Prechl, Z. Bajtay, and A. Erdei Complement Receptor Type 1 (CD35) Mediates Inhibitory Signals in Human B Lymphocytes J. Immunol., March 15, 2002; 168(6): 2782 - 2788. [Abstract] [Full Text] [PDF]

				K. J. Marchbank, C. C. Watson, D. F. Ritsema, and V. M. Holers Expression of Human Complement Receptor 2 (CR2, CD21) in Cr2-/- Mice Restores Humoral Immune Function J. Immunol., September 1, 2000; 165(5): 2354 - 2361. [Abstract] [Full Text] [PDF]